Huiyuan Li

机构：Changzhi Medical College, Chinese Academy of Medical Sciences & Peking Union Medical College, First People's Hospital of Yunnan Province, Zoucheng People's Hospital, Shanxi Jincheng Anthracite Mining Group (China), Institute of Hematology & Blood Diseases Hospital · ORCID：0000-0003-3242-1742

发表论文 141 篇 · 总被引 2186 次 · h-index 25

代表论文

• A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia (2024 · New England Journal of Medicine · 被引 48)
• Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial (2024 · Signal Transduction and Targeted Therapy · 被引 33)
• Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial (2025 · BMJ · 被引 6)
• Identification of a novel ferroptosis-induced immunogenic cell death related signature based on a machine learning framework in colorectal cancer (2025 · Discover Oncology · 被引 6)
• Formation behaviors of gas hydrates in water-in-oil emulsions with the coexistence of asphaltenes and resins (2024 · Colloids and Surfaces A Physicochemical and Engineering Aspects · 被引 5)
• Childhood and adolescent essential thrombocythemia and prefibrotic primary myelofibrosis: insights into diagnosis, outcomes, and treatment from a large Chinese cohort (2024 · Leukemia · 被引 4)